Valeant Pharmaceuticals targets buys in high-growth areas

Thu May 2, 2013 8:04am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

WINNIPEG, Manitoba May 2 (Reuters) - Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Thursday that the company would focus on acquisitions with strong cash flow in high growth areas, avoiding western Europe and Japan, where big pharmaceutical companies dominate.

A Valeant spokeswoman said the company would not comment on recent deal speculation, which has involved U.S. generic drugmaker Actavis Inc.